Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366401 | 1.00 | CYP2C19 (0.45) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6365584 | 0.77 | CYP2C19 (0.50) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6544313 | 0.75 | KDM4E (0.39) | USP2ALDH1A1TSHR | |
| SCHEMBL4689732 | 0.75 | CYP2C19 (0.48) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL16150052 | 0.75 | CYP2C19 (0.48) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL7696323 | 0.75 | CYP2C19 (0.48) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6545008 | 0.73 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL6860579 | 0.72 | CYP2C19 (0.45) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL4929033 | 0.68 | CYP2C19 (0.40) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL3345554 | 0.66 | CYP2C19 (0.58) | CYP2C19CYP1A2USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SOLCHEM ITALIANA S.P.A. (IT) | 2004-04-01 | — | — | US | claimed |
| EP-1373186-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | Solchem Italiana S.p.A (IT) | 2004-01-02 | — | — | EP | claimed |
| WO-2002074727-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | SOLCHEM ITALIANA S.P.A. (IT) | 2002-09-26 | — | — | WO | claimed |
| US-20050148792-A1 | Process for the preparation of gabapentin | GOPAL DAMODARAGOUNDER (US) | 2005-07-07 | — | — | US | disclosed |
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SOLCHEM ITALIANA S.P.A. (IT) | 2004-04-01 | — | — | US | disclosed |
| EP-1373186-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | Solchem Italiana S.p.A (IT) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074727-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | SOLCHEM ITALIANA S.P.A. (IT) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SLC7A1, MRPL21, BCAT1 | CYP2C19 1040/4885CYP1A2 2422/4885USP2 1762/4885 |
| US-20050148792-A1 | Process for the preparation of gabapentin | GABRE, GABRB2, GABRA4 | CYP2C19 379/4885CYP1A2 916/4885USP2 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.